TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open Label Study to Compare the Effect of Once Monthly Administration of Subcutaneous Mircera Versus Epoetin Alfa on Maintenance of Hemoglobin Levels, Safety and Tolerability in Dialysis Patients With Chronic Renal Anemia.
Brief Summary: This 2 arm study will compare the efficacy and safety of monthly administration of subcutaneous Mircera versus epoetin alfa for the maintenance of hemoglobin levels in dialysis patients with chronic renal anemia. Patients currently receiving maintenance treatment with epoetin alfa will be randomized to receive either monthly injections of Mircera with a starting dose (120, 200 or 360 micrograms) derived from the dose of epoetin alfa they were receiving in the week preceding study start, or to continue on epoetin alfa treatment. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: C.E.R.A. 120, 200, or 360 mcg; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): C.E.R.A. 120, 200, or 360 mcg
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): 2
D: Arm Label: C.E.R.A.; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): C.E.R.A.

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome
Brief Summary: -Intranasal budesonide therapy may lead to improved symptoms and sleep study findings in children with mild obstructive sleep apnea with and without allergic rhinitis that would not be treated with T\&A. The aim of the study is to conduct a randomized double blind cross-over trial comparing the effect of once a day intranasal budesonide therapy vs. placebo in children with mild sleep apnea that would not be candidates for T\&A.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: donepezil | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DEVICE; Name: CPAP (Continuous Positive Airway Pressure); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome
Brief Summary: -Intranasal budesonide therapy may lead to improved symptoms and sleep study findings in children with mild obstructive sleep apnea with and without allergic rhinitis that would not be treated with T\&A. The aim of the study is to conduct a randomized double blind cross-over trial comparing the effect of once a day intranasal budesonide therapy vs. placebo in children with mild sleep apnea that would not be candidates for T\&A.


Options:
A: Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Early AT Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Adenotonsillectomy (AT) - removal of adenoids and tonsils | Arm Label: Watchful Waiting; Type: OTHER; Interventions: Other: Watchful Waiting | Intervention Type: PROCEDURE; Name: Adenotonsillectomy (AT) - removal of adenoids and tonsils; Assigned to Arm(s): Early AT Surgery | Intervention Type: OTHER; Name: Watchful Waiting; Assigned to Arm(s): Watchful Waiting
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Aerosal; Type: EXPERIMENTAL; Interventions: Device: Halotherapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo | Intervention Type: DEVICE; Name: Halotherapy; Assigned to Arm(s): Aerosal | Intervention Type: DEVICE; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured With Recombinant Human Albumin (rHA) When Administered to Children in Their Second Year of Life
Brief Summary: Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life.

Secondary objectives: To describe the safety profile of a first dose of ProQuad® manufactured with rHA when administered to children in their second year of life.


Options:
A: Arm Label: GSK1437173A 18-30 Years Old Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling for assay of persistence of immunogenicity | Arm Label: GSK1437173A 50-70 Years Old Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling for assay of persistence of immunogenicity | Intervention Type: PROCEDURE; Name: Blood sampling for assay of persistence of immunogenicity; Assigned to Arm(s): GSK1437173A 18-30 Years Old Group, GSK1437173A 50-70 Years Old Group
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Priorix-Tetra™ (MMRV vaccine 208136), Biological: Havrix®, Biological: Prevnar® | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: Priorix-Tetra™ (MMRV vaccine 208136), Biological: Havrix®, Biological: Prevnar® | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Biological: ProQuad®, Biological: Havrix®, Biological: Prevnar® | Intervention Type: BIOLOGICAL; Name: Priorix-Tetra™ (MMRV vaccine 208136); Assigned to Arm(s): Group A, Group B | Intervention Type: BIOLOGICAL; Name: ProQuad®; Assigned to Arm(s): Group C | Intervention Type: BIOLOGICAL; Name: Havrix®; Assigned to Arm(s): Group A, Group B, Group C | Intervention Type: BIOLOGICAL; Name: Prevnar®; Assigned to Arm(s): Group A, Group B, Group C
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: Varicella-zoster vaccine | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Varicella-zoster vaccine; Assigned to Arm(s): Arm 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Arm 2
D: Arm Label: ProQuad®; Type: EXPERIMENTAL; Interventions: Biological: ProQuad® | Intervention Type: BIOLOGICAL; Name: ProQuad®; Assigned to Arm(s): ProQuad®

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome
Brief Summary: The purpose of this research is to determine the effect of adenotonsillectomy surgery (removal of tonsils and adenoids) on obstructive sleep apnea syndrome (OSAS) in children. OSAS can cause health problems including poor growth, high blood pressure, diabetes and behavioral and learning difficulties. Although adenotonsillectomy is the usual treatment for children with OSAS, it is not known with any certainty if the child's OSAS symptoms improve afterwards. This study will help determine if improvement occurs or if it does not. It will also look at whether certain groups, such as children who are overweight or of different ethnicities, are helped by the surgery.


Options:
A: Arm Label: Aerosal; Type: EXPERIMENTAL; Interventions: Device: Halotherapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo | Intervention Type: DEVICE; Name: Halotherapy; Assigned to Arm(s): Aerosal | Intervention Type: DEVICE; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Early AT Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Adenotonsillectomy (AT) - removal of adenoids and tonsils | Arm Label: Watchful Waiting; Type: OTHER; Interventions: Other: Watchful Waiting | Intervention Type: PROCEDURE; Name: Adenotonsillectomy (AT) - removal of adenoids and tonsils; Assigned to Arm(s): Early AT Surgery | Intervention Type: OTHER; Name: Watchful Waiting; Assigned to Arm(s): Watchful Waiting
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 1-dose Regimen and Different 2-dose Regimens of a Zoster Vaccine (Live), ZOSTAVAX ®, in Subjects ≥ 70 Years of Age
Brief Summary: Primary objective:

Immunogenicity To demonstrate that a second dose of ZOSTAVAX® elicits higher varicella-zoster virus (VZV) antibody titres than a first dose of ZOSTAVAX® whether given as a 0-1 month schedule or as a 0-3 month schedule in subjects ≥70 years of age as measured at 4 weeks post-vaccination

Secondary objectives Immunogenicity

* To summarise the VZV antibody titres at 4 weeks post-vaccination after a 1-dose regimen and 4 weeks post-vaccination after each dose of each 2-doses regimen of ZOSTAVAX®.
* To compare the VZV antibody titres at 12 months after completion of a 1-dose regimen with the VZV antibody titres at 12 months after completion of each 2-doses regimen of ZOSTAVAX®
* To summarise the VZV antibody titres at 24 and 36 months after completion of a 1-dose regimen and at 24 and 36 months after completion of each 2-doses regimen of ZOSTAVAX®


Options:
A: Arm Label: GSK1437173A group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster Vaccine GSK1437173A | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes Zoster Vaccine GSK1437173A; Assigned to Arm(s): GSK1437173A group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo group
B: Arm Label: Single Dose of Zostavax; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 1; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 3; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Intervention Type: BIOLOGICAL; Name: Zostavax; Assigned to Arm(s): Single Dose of Zostavax, Zostavax - Day 0 and Month 1, Zostavax - Day 0 and Month 3
C: Arm Label: GSK1437173A 18-30 Years Old Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling for assay of persistence of immunogenicity | Arm Label: GSK1437173A 50-70 Years Old Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling for assay of persistence of immunogenicity | Intervention Type: PROCEDURE; Name: Blood sampling for assay of persistence of immunogenicity; Assigned to Arm(s): GSK1437173A 18-30 Years Old Group, GSK1437173A 50-70 Years Old Group
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: Varicella-zoster vaccine | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Varicella-zoster vaccine; Assigned to Arm(s): Arm 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Prospective Study Comparing High Dose Continuous Venovenous Hemodiafiltration (CVVHDF) to Standard Dose CVVHDF in Critically Ill Patients With Acute Renal Failure at the University of Alabama at Birmingham
Brief Summary: In the last three decades, the mortality associated with acute renal failure (ARF) in the ICU has remained unchanged at greater than 50%, despite improvements in dialysis technology.

The primary objective is to determine whether Continuous Veno-Venous Hemodiafiltration (CVVHDF) using an ultrafiltration rate of 35 ml/hr/kg (high dose) leads to a greater reduction in all-cause ICU mortality compared to standard CVVHDF using an ultrafiltration rate of 20 ml/hr/kg.


Options:
A: Arm Label: Femoral route; Type: EXPERIMENTAL; Interventions: Procedure: Femoral route for hemodialysis | Arm Label: Jugular route; Type: EXPERIMENTAL; Interventions: Procedure: Jugular route for hemodialysis | Intervention Type: PROCEDURE; Name: Femoral route for hemodialysis; Assigned to Arm(s): Femoral route | Intervention Type: PROCEDURE; Name: Jugular route for hemodialysis; Assigned to Arm(s): Jugular route
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard dose of dialysis | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: High dose of dialysis | Intervention Type: DEVICE; Name: Standard dose of dialysis; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: High dose of dialysis; Assigned to Arm(s): 2
C: Arm Label: High citrate group; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Arm Label: Low citrate group; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): High citrate group, Low citrate group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: High cut-off (super high flux) polyamide membrane | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard polyamide high flux membrane | Intervention Type: DEVICE; Name: Standard polyamide high flux membrane; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: High cut-off (super high flux) polyamide membrane; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxaliplatin Based Regimen
Brief Summary: The main objective of the study was to evaluate the effectiveness of aflibercept (versus placebo) in increasing the overall survival in participants with metastatic colorectal cancer treated with FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) and that have previously failed an oxaliplatin based treatment for metastatic disease.

The secondary objectives were to compare progression-free survival, to evaluate overall response rate, to evaluate the safety profile, to assess immunogenicity of intravenous (IV) aflibercept, and to assess pharmacokinetics of IV aflibercept in both treatment arms.


Options:
A: Arm Label: Placebo/FOLFIRI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Arm Label: Aflibercept/FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Aflibercept/FOLFIRI
B: Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: leucovorin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): N/A
C: Arm Label: Panitumumab plus best supportive care; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Arm Label: Best Supportive Care; Type: OTHER; Interventions: Other: Best supportive care | Intervention Type: OTHER; Name: Best supportive care; Assigned to Arm(s): Best Supportive Care | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab plus best supportive care
D: Arm Label: Regorafenib (Stivarga, BAY73-4506)+BSC; Type: EXPERIMENTAL; Interventions: Drug: Regorafenib (Stivarga, BAY73-4506), Other: Best Supportive Care (BSC) | Arm Label: Placebo+BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Regorafenib (Stivarga, BAY73-4506); Assigned to Arm(s): Regorafenib (Stivarga, BAY73-4506)+BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+BSC | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Placebo+BSC, Regorafenib (Stivarga, BAY73-4506)+BSC

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PROTECT II: A Prospective, Multi-center, Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5 System Versus Intra Aortic Balloon Pump (IABP)in Patients Undergoing Non Emergent High Risk PCI
Brief Summary: The IMPELLA® 2.5 System will be superior to Intra Aortic Balloon Pump in preventing the composite rate of major adverse events during and after the PCI procedure.


Options:
A: Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin | Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): Enoxaparin
B: Arm Label: IMPELLA LP 2.5; Type: EXPERIMENTAL; Interventions: Device: IMPLELLA LP 2.5 | Arm Label: IABP Intra-aortic balloon pump; Type: ACTIVE_COMPARATOR; Interventions: Device: IABP Intra-aortic balloon pump | Intervention Type: DEVICE; Name: IMPLELLA LP 2.5; Assigned to Arm(s): IMPELLA LP 2.5 | Intervention Type: DEVICE; Name: IABP Intra-aortic balloon pump; Assigned to Arm(s): IABP Intra-aortic balloon pump
C: Arm Label: Intraaortic balloon pump; Type: ACTIVE_COMPARATOR; Interventions: Device: Intraaortic balloon pump | Arm Label: No intraaortic balloon pump; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Intraaortic balloon pump; Assigned to Arm(s): Intraaortic balloon pump
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Intraaortic Balloon Pump | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: Left Ventricular Assist Device Impella LP 2.5 | Intervention Type: DEVICE; Name: Left Ventricular Assist Device Impella LP 2.5; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Intraaortic Balloon Pump; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lantus vs Sulfonylurea as add-on Therapy in Type 2 Diabetic Patients Failing Metformin Monotherapy: Comparison of Effects on Beta Cell Function and Metabolic Profile.
Brief Summary: Primary objective:

To compare long-term glycemic control and preservation of beta cell function when basal insulin or sulfonylurea is added on metformin in the early Type 2 Diabetes Mellitus patients

Secondary objective:

To assess the change of insulin resistance, microvascular complication incidence, patient satisfaction with treatment


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine, Drug: Metformin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Metformin | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2
B: Arm Label: Saxagliptin, 5 mg + insulin; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, 5 mg + insulin | Arm Label: Placebo + insulin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + insulin | Intervention Type: DRUG; Name: Saxagliptin, 5 mg + insulin; Assigned to Arm(s): Saxagliptin, 5 mg + insulin | Intervention Type: DRUG; Name: Placebo + insulin; Assigned to Arm(s): Placebo + insulin
C: Arm Label: Sitagliptin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: sitagliptin (MK0431) | Arm Label: Glipizide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: glipizide | Intervention Type: DRUG; Name: sitagliptin (MK0431); Assigned to Arm(s): Sitagliptin 100 mg | Intervention Type: DRUG; Name: Comparator: glipizide; Assigned to Arm(s): Glipizide
D: Arm Label: Vildagliptin + placebo to Gliclazide; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: Metformin, Drug: Placebo to Gliclazide | Arm Label: Gliclazide + placebo to Vildagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gliclazide, Drug: Metformin, Drug: Placebo to Vildagliptin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Gliclazide; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin, Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Gliclazide; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Vildagliptin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin

Answer: A